Objectives To define a clinically meaningful treatment response definition for haemolytic anaemia, that will form part of a ...

Objective The aim of this study was to assess the epidemiological and clinical characteristics of herpes zoster (HZ) and to ...

Objective Systemic lupus erythematosus (SLE) primarily affects women of reproductive age, necessitating complex conversations ...

Background/objective To reduce the risk of hydroxychloroquine (HCQ)-induced retinopathy, the American Academy of ...

Objective To evaluate the safety and durability of telitacicept treatment in patients with SLE by identifying the reasons for ...

Introduction Osteoporosis and fragility fracture are more frequently found in systemic lupus erythematosus (SLE) patients ...

Objective To evaluate the efficacy of mepacrine (MC) as an add-on therapy in patients with SLE unresponsive to hydroxychloroquine (HCQ)-containing regimens at 6 months after MC introduction. Methods ...

Objective Lupus nephritis (LN) is a major complication and cause of death among patients with SLE. This research used in vivo and in vitro experiments to explore the therapeutic potential of metformin ...

Objective To assess the appropriateness of expanded serological activity eligibility criteria for belimumab use in the UK systemic lupus erythematosus (SLE) population (and possibly other countries), ...

Objective Early prediction of long-term outcomes in patients with systemic lupus erythematosus (SLE) remains a great challenge in clinical practice. Our study aims to develop and validate predictive ...

Background SLE has increased risk of invasive pneumococcal disease due to immune dysregulation and immunosuppression. European Alliance of Associations for Rheumatology recommendations suggest ...

Cyclophosphamide (CyP) is perhaps the most venerable of immunosuppressants used to treat lupus nephritis (LN). Its use was established in the so-called NIH regimen in the 1980s and high-dose monthly ...